Lilly-Foghorn Cancer Drug Partnership Ends After Clinical Setback

Eli Lilly and biotechnology company Foghorn Therapeutics have ended a major cancer-drug collaboration after clinical data failed to show enough benefit to justify moving the treatment forward.

The companies have decided to discontinue development of FHD-909, an experimental drug designed to target SMARCA2 in cancers carrying certain SMARCA4 mutations. The treatment was being evaluated in a Phase 1 trial, including patients with non-small cell lung cancer. After reviewing dose-escalation data, the companies concluded that the drug was not producing the level of efficacy needed for further development.

The decision also ends work on a related SMARCA2 degrader programme and another undisclosed oncology target covered by the partnership.

The setback is particularly significant for Foghorn. Lilly originally entered the collaboration in 2021 with a $300 million upfront payment and an $80 million equity investment, alongside potential future payments tied to development milestones.

Following the collapse of the partnership, Foghorn announced plans to reduce its workforce by approximately 40%, leaving the company with about 65 employees. It plans to redirect resources toward its remaining experimental programmes, including treatments targeting EP300 and CBP-related cancers.

The development highlights one of biotechnology's biggest risks: promising laboratory science does not always translate into effective treatments in human trials. For drug developers and investors, the outcome also demonstrates how quickly disappointing clinical results can reshape partnerships, research priorities and company finances.